相关实验视频

Updated: Jun 29, 2025

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

勒卡尼迪平的抗氧化作用可以防止噪音引起的听力损失

Zhaoqi Guo¹, E Tian¹, Sen Chen¹

¹Department of Otorhinolaryngology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

Antioxidants (Basel, Switzerland)

|March 28, 2024

概括

勒卡尼迪平通过保护听觉毛细胞,在预防噪音引起的听力损失 (NIHL) 中表现有前途. 这种L型通道阻断剂在暴露于噪音的小鼠中显示出显著的抗氧化作用和保持听力值.

科学领域:

耳鼻药理学耳鼻药理学耳鼻药理学
神经科学是一个神经科学.
细胞生物学细胞生物学

背景情况:

噪音引起的听力损失 (NIHL) 是一种常见的损伤,与听觉毛细胞中的氧化应激有关.
L型通道阻断剂,一种二皮里丁类药物,已经显示出减轻毛发细胞损伤的潜力.
第三代二皮里丁,特别是勒卡尼迪平,对NIHL的疗效尚未得到充分证实.

研究的目的:

调查勒卡尼迪平对噪音引起的听力损失的保护作用.
评估lercanidipine在听觉细胞中的抗氧化机制.
评估勒卡尼迪平作为NIHL预防治疗剂的潜力.

主要方法:

使用葡萄糖氧化酶 (GO) 处理的OC1细胞系和耳扩展剂来评估lercanidipine的保护作用.
在体内给噪声暴露的小鼠服用勒卡尼迪平,以评估听力值.
分析了抗氧化剂和氧化酶基因的mRNA表达,并量化了氧化应激标志物 (3NT,4HNE).

主要成果:

勒卡尼迪平显著改善了耳扩张器中的OC1细胞活力和外毛细胞 (OHC) 存活率.
勒卡尼迪平治疗增加了抗氧化酶基因表达 (HO-1,SOD1/2,Txnrd1) 和减少了氧化酶基因表达 (COX-2,iNOS).
在体内,在暴露于噪音之前和之后给予勒卡尼迪平,可保持听力值和OHC群体,显示持续的抗氧化作用.

结论:

勒卡尼迪平有效地减轻噪音引起的听力损失,并保护基底转移OHC存活率.
勒卡尼迪平的保护机制涉及显著的抗氧化特性.
勒卡尼迪平为预防噪音引起的听力损失提供了一个有希望的临床选择.

关键词:

莱尔卡尼迪皮因 (Lercanidipine) 是一种噪音引起的听力损失氧化应激是一种氧化应激.

更多相关视频

Modified Experimental Conditions for Noise-Induced Hearing Loss in Mice and Assessment of Hearing Function and Outer Hair Cell Damage

Modified Experimental Conditions for Noise-Induced Hearing Loss in Mice and Assessment of Hearing Function and Outer Hair Cell Damage

Published on: February 10, 2023

Cochlear Surface Preparation in the Adult Mouse

Cochlear Surface Preparation in the Adult Mouse

Published on: November 6, 2019

相关概念视频

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...